phrykt

Vistagen Therapeutics, Inc. (VTGN): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of VTGN were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No VTGN insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VTGN short interest

Moderate short interest. 6.1% of VTGN shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 38%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.49M VTGN shares were sold short, 6.1% of the shares outstanding, up 0.6% from the report before. At the average daily volume of 728,036 shares, buying them all back would take about 3.4 trading days (days to cover).

Shares short, % of all shares

6.06%May 15Oct 309.93%

Days to cover

3.4May 15Oct 308.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.49M6.06%+1%728,0363.4
Oct 15, 20262.47M6.03%-34%1.14M2.2
Sep 30, 20263.75M9.14%+39%55.16M1.0
Sep 15, 20262.71M6.60%+27%354,1487.6
Aug 31, 20262.13M5.18%+9%762,7702.8
Aug 14, 20261.95M4.76%-3%13.06M1.0
Jul 31, 20262.01M4.89%+26%823,2692.4
Jul 15, 20261.60M3.89%+0%3.31M1.0
Jun 30, 20261.59M3.88%-7%5.77M1.0
Jun 15, 20261.71M4.16%-16%705,9562.4
May 29, 20262.02M5.10%+12%503,2024.0
May 15, 20261.80M4.54%+2%1.12M1.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vistagen Therapeutics company events

Vistagen Therapeutics filed 30 reports on Form 8-K in the last 12 months, 12 of them about an important change (leadership, listing, job cuts). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementVistagen Therapeutics, Inc. announced a regulatory update from its recent, productive Type C meeting with the U.S. Food and Drug Administration to discuss potential registrational paths forward for the development of its lead product candidate, fasedienol, in social anxiety disorder. Filing
  2. Oct 30, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  3. Oct 9, 2026LeadershipThe Board of Directors of Vistagen Therapeutics, Inc. approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and described in the Company’s Quarterly Report on Form 10-Q for the period ended June 30… Filing
  4. Sep 25, 2026AnnouncementShared information with investors. Filing
  5. Sep 24, 2026AnnouncementVistagen Therapeutics, Inc. issued a press release summarizing positive exploratory efficacy data presented by the Company at Psych Congress 2026. Filing
  6. Sep 22, 2026AnnouncementVistagen Therapeutics, Inc. issued a press release to announce preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. Filing
  7. Sep 11, 2026VoteReported shareholder vote results. Filing
  8. Aug 14, 2026ResultsReleased financial results. Filing
  9. Aug 6, 2026AnnouncementThe Company announced the topline results of its three-arm, multicenter, randomized, double-blind, placebo controlled exploratory Phase 2 clinical trial (N=61) designed to assess the efficacy, safety, and tolerability of two 3.2 µg doses of fasedienol administered ten minutes apart compared with a… Filing
  10. Aug 5, 2026ListingVistagen Therapeutics, Inc. received an extension notification from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC granting the Company a 180-day extension, until February 1, 2027, to regain compliance with the requirement for the Company’s common stock, par value $0.001 per… Filing
  11. Jul 31, 2026LeadershipThe Board of Directors of Vistagen Therapeutics, Inc., upon recommendation from the Corporate Governance and Nominating Committee of the Board, unanimously approved of the appointment of Douglas J. Williamson, M.D. as a director to serve until the Company’s next annual meeting of stockholders or… Filing
  12. Jun 30, 2026AnnouncementThe Company announced that the PALISADE-4 Phase 3 trial of intranasal fasedienol did not achieve its primary endpoint, as measured by the least squares mean change from baseline on the Subjective Units of Distress Scale score for fasedienol (-9.5+/-1.7 standard error) compared with placebo… Filing
  13. Jun 17, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  14. Jun 15, 2026ResultsReleased financial results. Filing
  15. Jun 9, 2026AnnouncementVistagen Therapeutics, Inc. issued a press release to announce that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing… Filing
  16. May 19, 2026LeadershipVistagen Therapeutics, Inc. appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer. Filing
  17. May 12, 2026AnnouncementVistagen Therapeutics, Inc. issued a press release to announce preliminary positive data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. Filing
  18. May 8, 2026AnnouncementVistagen Therapeutics, Inc. issued a press release to announce, among other things, that the last patient has completed their last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating fasedienol nasal spray for the acute… Filing
  19. Apr 28, 2026AnnouncementVistagen Therapeutics, Inc. issued a press release to announce that the Company has received a “Study May Proceed” letter from the U.S. Food and Drug Administration under its U.S. Investigational New Drug application for refisolone nasal spray, the Company’s non-hormonal, non-systemic product… Filing
  20. Apr 13, 2026LeadershipThe Compensation Committee of the Board of Directors of Vistagen Therapeutics, Inc., in consultation with the Company’s independent compensation consultant, approved of retention awards in the form of a stock option grant to all Company employees, including the following executives who each… Filing
  21. Apr 2, 2026ListingVistagen Therapeutics, Inc. notified The Nasdaq Stock Market LLC of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other… Filing
  22. Mar 18, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  23. Mar 16, 2026AnnouncementShared information with investors. Filing
  24. Mar 11, 2026AnnouncementVistagen Therapeutics, Inc. implemented a Board approved reduction in its workforce by approximately 20%. Filing
  25. Feb 20, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  26. Feb 12, 2026ResultsReleased financial results. Filing
  27. Feb 6, 2026ListingVistagen Therapeutics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, for the last 30 consecutive business days, the Company is not currently in… Filing
  28. Jan 9, 2026AnnouncementShared information with investors. Filing
  29. Dec 22, 2025AnnouncementVistagen Therapeutics, Inc. announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint, as measured by the least squares (" LS" ) mean change from baseline on the the Subjective Units of Distress Scale… Filing
  30. Dec 3, 2025LeadershipThe Board of Directors of Vistagen Therapeutics, Inc. appointed Nick B. Tressler to serve as the Company’s Chief Financial Officer and Treasurer, effective December 1, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vistagen Therapeutics financials

Famous investors that hold VTGN

1 of the 50 well-known investors we track reported holding VTGN in their latest 13F filing. The largest position is Jim Simons's, worth $460K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.49M$460K0.0%+105%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named VTGN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A1.9%
Nov 16, 2026Commodore Capital LP13G/A3.7%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A1.9%
Nov 16, 2026Commodore Capital LP13G/A3.7%

Questions about Vistagen Therapeutics, Inc. (VTGN) stock

Are VTGN insiders buying or selling?

No VTGN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in VTGN?

As of Oct 30, 2026, 2.49M VTGN shares were sold short, 6.1% of the shares outstanding, up 0.6% from the report before. At the average daily volume of 728,036 shares, buying them all back would take about 3.4 trading days (days to cover). See the history.

Which famous investors hold VTGN?

1 of the 50 well-known investors we track reported VTGN in their latest 13F filing, including Jim Simons. The largest position is worth $460K. See all holders.

Executive pay

Vistagen Therapeutics's chief executive was paid a total of $1.2M for the year ended Mar 31, 2026, down 51% from $2.5M the year before. In the last 12 months, Vistagen Therapeutics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.2MYear ended Mar 31, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$132KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$701KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.